Literature DB >> 10570800

Recombinant protein composed of Pseudomonas exotoxin A, outer membrane proteins I and F as vaccine against P. aeruginosa infection.

T Y Chen1, H F Shang, T L Chen, C P Lin, C F Hui, J Hwang.   

Abstract

We have constructed a chimeric protein composed of the receptor binding and membrane translocation domains of Pseudomonas exotoxin A (PE) with the outer membrane proteins I and F, together designated as PEIF. The potential of PEIF as a vaccine against Pseudomonas infection was evaluated in BALB/c mice and New Zealand white rabbits. We examined titers of anti-PE and anti-OprF antibodies, and the ability both to neutralize PE cytotoxicity and to increase opsonophagocytic uptake of Pseudomonas aeruginosa strain PAO1, serogroups 2 and 6. The results showed that PEIF can induce antibodies not only to neutralize the PE cytotoxicity but also to promote the uptake of various strains of P. aeruginosa by murine peritoneal macrophages. In a burned mouse model, PEIF afforded significant protection against infection by the homologous P. aeruginosa strain PAO1, heterologous serogroup 2, and the PE hyperproducing strain PA103. These observations thus indicate that PEIF may be used as a novel vaccine against P. aeruginosa infection.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10570800     DOI: 10.1007/s002530051555

Source DB:  PubMed          Journal:  Appl Microbiol Biotechnol        ISSN: 0175-7598            Impact factor:   5.560


  7 in total

Review 1.  Recent developments for Pseudomonas vaccines.

Authors:  Anurag Sharma; Anja Krause; Stefan Worgall
Journal:  Hum Vaccin       Date:  2011-10-01

2.  Cloning, expression and characterization of recombinant exotoxin A-flagellin fusion protein as a new vaccine candidate against Pseudomonas aeruginosa infections.

Authors:  Asghar Tanomand; Safar Farajnia; Shahin Najar Peerayeh; Jafar Majidi
Journal:  Iran Biomed J       Date:  2013

3.  Protective effect of DNA vaccine encoding pseudomonas exotoxin A and PcrV against acute pulmonary P. aeruginosa Infection.

Authors:  Mingzi Jiang; Jing Yao; Ganzhu Feng
Journal:  PLoS One       Date:  2014-05-01       Impact factor: 3.752

4.  Construction of a Protective Vaccine Against Lipopolysaccharide-Heterologous Pseudomonas aeruginosa Strains Based on Expression Profiling of Outer Membrane Proteins During Infection.

Authors:  Chang Liu; Xiaolei Pan; Bin Xia; Fei Chen; Yongxin Jin; Fang Bai; Gregory Priebe; Zhihui Cheng; Shouguang Jin; Weihui Wu
Journal:  Front Immunol       Date:  2018-07-26       Impact factor: 7.561

Review 5.  Understanding Pseudomonas aeruginosa-Host Interactions: The Ongoing Quest for an Efficacious Vaccine.

Authors:  Maite Sainz-Mejías; Irene Jurado-Martín; Siobhán McClean
Journal:  Cells       Date:  2020-12-05       Impact factor: 6.600

6.  Vaccination to Prevent Pseudomonas aeruginosa Bloodstream Infections.

Authors:  Robert J Hart; Lisa A Morici
Journal:  Front Microbiol       Date:  2022-03-28       Impact factor: 5.640

7.  SV40 Pseudovirion gene delivery of a toxin to treat human adenocarcinomas in mice.

Authors:  C Kimchi-Sarfaty; W D Vieira; D Dodds; A Sherman; R J Kreitman; S Shinar; M M Gottesman
Journal:  Cancer Gene Ther       Date:  2006-02-24       Impact factor: 5.854

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.